Repository logo
 
Publication

Off-label use of bevacizumab in age-related macular degeneration: protocol for a systematic review and meta-analysis

2022-04Preprint Open access
Simple item page
dc.contributor.authorEstarreja, João
dc.contributor.authorValente, Carina
dc.contributor.authorSilva, Carina
dc.contributor.authorCamacho, Pedro
dc.contributor.authorMateus, Vanessa
dc.date.accessioned2022-08-03T11:47:19Z
dc.date.available2022-08-03T11:47:19Z
dc.date.issued2022-04
dc.description.abstractBackground: Age-related macular degeneration (AMD) is recognized as the leading cause of vision loss in elderly people. Taking into account the phenomenon of aging worldwide, the prevalence of AMD is expected to increase gradually in the future. AMD can be divided into early, intermediate and late stages, where early and intermediate are mainly asymptomatic, late-stage can be classified as non-vascular AMD and vascular AMD. Current pharmacological treatment in vascular AMD includes the administration of anti-VEGF agents, such as ranibizumab, pegaptanib, and aflibercept. Additionally, it has been reported that the off-label use of bevacizumab, through intravitreal administrations, demonstrates to be effective along with a lower cost in comparison to other agents used, which makes it a new possible pharmacological approach. Objective: This review aims to evaluate the efficacy, safety, and efficiency of the use of bevacizumab in the treatment of neovascular AMD. Methods: To identify and select relevant articles present in current literature, it will be developed a highly sensitive search strategy. To develop this search, it will be used MEDLINE via the Pubmed platform. It will be only considered randomized controlled clinical trials, where it is compared the use of bevacizumab with another pharmacological agent, such as ranibizumab, or even a placebo, in patients aged 50 years and older, diagnosed with vascular AMD. Results: This project has no funding and it has been done by a multidisciplinary research team of pharmacologists and orthoptists. The study was initiated in May 2021 with the lineation of the protocol, now the data are been extracted and analyzed, and it is expected to be released by the end of 2022. Conclusions: This review will provide a synthesis of the current information and underlying evidence, about the influence of the off-label use of bevacizumab in this disease. Altogether, it will allow having a clearer vision of a new possible accepted pharmacological approach for the treatment of vascular AMD. Clinical Trial: The protocol for this review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) with the code CRD42021244931.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEstarreja J, Valente C, Silva C, Camacho P, Mateus V. Off-label use of bevacizumab in age-related macular degeneration: protocol for a systematic review and meta-analysis [preprint]. JMIR Res Protocols. 2022 April 12:38658.pt_PT
dc.identifier.doi10.2196/preprints.38658pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/14909
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherJMIR Publicationspt_PT
dc.relation.publisherversionhttps://preprints.jmir.org/preprint/38658pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectOphthalmologypt_PT
dc.subjectWet macular degenerationpt_PT
dc.subjectAge-related macular degenerationpt_PT
dc.subjectBevacizumabpt_PT
dc.subjectDrug therapypt_PT
dc.titleOff-label use of bevacizumab in age-related macular degeneration: protocol for a systematic review and meta-analysispt_PT
dc.typepreprint
dspace.entity.typePublication
oaire.citation.titleJMIR Research Protocolspt_PT
person.familyNameEstarreja
person.familyNameSilva
person.familyNameCamacho
person.familyNamePinho Mateus
person.givenNameJoão
person.givenNameCarina
person.givenNamePedro
person.givenNameVanessa Alexandra
person.identifier.ciencia-idEB19-EDA2-704B
person.identifier.ciencia-id2411-5936-0820
person.identifier.ciencia-id271F-B4E1-014E
person.identifier.ciencia-id5A12-571D-AD6A
person.identifier.orcid0000-0002-8283-3174
person.identifier.orcid0000-0003-1021-7935
person.identifier.orcid0000-0002-2986-5652
person.identifier.orcid0000-0002-3204-3772
person.identifier.scopus-author-id55258764900
rcaap.rightsopenAccesspt_PT
rcaap.typepreprintpt_PT
relation.isAuthorOfPublicationd16a20d0-ac73-4989-b83d-abeab53139f7
relation.isAuthorOfPublication81a5cd80-1982-43ba-bde5-4c43ae0e5234
relation.isAuthorOfPublicationc41e9c52-157e-4375-8005-b609cfc374e7
relation.isAuthorOfPublication406041a5-682c-4f94-a4e2-ddbfc541313c
relation.isAuthorOfPublication.latestForDiscoveryc41e9c52-157e-4375-8005-b609cfc374e7

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Off-label use of bevacizumab in age-related macular degeneration_protocol for a systematic review and meta-analysis.pdf
Size:
479.53 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Artigos